Survival of patients eligible for stem cell transplantation.

Kaplan-Meier landmark survival estimates (with a 90-day landmark period) for patients eligible for HSCT (A) according to the existence of an allogeneic donor (N = 103 patients) (relative risk in the no-donor group, 1.71; 95% confidence interval, 1.09 to 2.68;P = .02 by the log-rank test) and (B) according to theBCR-ABL status after 2 courses of chemotherapy (N = 63 patients) (relative risk in the BCR-ABL⁺ group, 2.46; 95% confidence interval, 1.26 to 4.78; P = .006 by the log-rank test).